Skip to main content

Drug Interactions between BexxarTherapeutic and ibritumomab

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

ibritumomab tiuxetan tositumomab

Applies to: ibritumomab and BexxarTherapeutic (tositumomab)

MONITOR CLOSELY: Coadministration of tositumomab and iodine I 131 tositumomab with drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Tositumomab and iodine I 131 tositumomab alone can cause severe or life-threatening thrombocytopenia. In premarketing clinical studies, NCI CTC grade 3 and 4 thrombocytopenia occurred in 53% of 230 patients, and sequelae included hemorrhage in 12% and requirement of platelet transfusions in 15% of patients. The time to thrombocyte nadir was 4 to 7 weeks and the duration of thrombocytopenia was approximately 30 days. However, 7% of the patients experienced thrombocytopenia that extended beyond 90 days following administration of the therapeutic regimen.

MANAGEMENT: Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously. Close clinical and laboratory observation for bleeding complications is recommended during and after the therapeutic regimen. A complete blood count (CBC) with differential and platelet count should be obtained prior to and at least weekly for a minimum of 10 weeks after treatment.

References

  1. "Product Information. Bexxar I 131 Therapeutic (iodine I 131 tositumomab)." GlaxoSmithKline (2022):
  2. "Product Information. BexxarTherapy (tositumomab)." GlaxoSmithKline Inc (2006):

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Cd20 monoclonal antibodies

Therapeutic duplication

The recommended maximum number of medicines in the 'CD20 monoclonal antibodies' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'CD20 monoclonal antibodies' category:

  • BexxarTherapeutic (tositumomab)
  • ibritumomab

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer